Decision Making in Health and Medicine: Estimation, calibration, and validation

Essentially, all models are wrong, but some are useful. George E. P. Box Introduction As discussed in Chapter 8, ‘good decision analyses depend on both the veracity of the decision model and the validity of the individual data elements.’ The validity of each individual data element relies on the comprehensiveness of the literature search for the best and most appropriate study or studies, criteria for selecting the source studies, the design of the study or studies, and methods for synthesizing the data from multiple sources. Nonetheless, Sir Michael David Rawlins avers that ‘Decision makers have to incorporate judgements, as part of their appraisal of the evidence, in reaching their conclusions. Such judgements relate to the extent to which each of the components of the evidence base is “fit for purpose.” Is it reliable?’(1) Because the integration of a multitude of these ‘best available’ data elements forms the basis for model results, some individuals refer to decision analyses as black boxes, so this last question applies particularly to the overall model predictions. Consequently, assessing model validity becomes paramount. However, prior to assessing model validity, model construction requires attention to parameter estimation and model calibration. This chapter focuses on parameter estimation, calibration, and validation in the context of Markov and, more generally, state-transition models (Chapter 10) in which recurrent events may occur over an extended period of time. The process of parameter estimation, calibration, and validation is iterative: it involves both adjustment of the data to fit the model and adjustment of the model to fit the data. Parameter estimation Survival analysis involves determining the probability that an event such as death or disease progression will occur over time. The events modeled in survival analysis are called ‘failure’ events, because once they occur, they cannot occur again. ‘Survival’ is the absence of the failure event. The failure event may be death, or it may be death combined with a non-fatal outcome such as developing cancer or having a heart attack, in which case the absence of the event is referred to as event-free survival. Commonly used methods for survival analysis include life-table analysis, Kaplan–Meier product limit estimates, and Cox proportional hazards models. A survival curve plots the probability of being alive over time (Figure 11.1).

[1]  J. Wong,et al.  Watchful Waiting with Periodic Liver Biopsy versus Immediate Empirical Therapy for Histologically Mild Chronic Hepatitis C: A Cost-Effectiveness Analysis , 2000, Annals of Internal Medicine.

[2]  L. Goldman,et al.  The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. , 1997, JAMA.

[3]  M. Rawlins De testimonio: on the evidence for decisions about the use of therapeutic interventions , 2008, The Lancet.

[4]  S. Palmer,et al.  The CHD challenge: comparing four cost-effectiveness models. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[5]  Yen Lin Chia,et al.  Simulation-based parameter estimation for complex models: a breast cancer natural history modelling illustration , 2004, Statistical methods in medical research.

[6]  J. Savarino,et al.  Bayesian Calibration of Microsimulation Models , 2009, Journal of the American Statistical Association.

[7]  S G Pauker,et al.  Kidney Failure or Cancer , 1984, Medical decision making : an international journal of the Society for Medical Decision Making.

[8]  Natasha K. Stout,et al.  Chapter 7: The Wisconsin Breast Cancer Epidemiology Simulation Model , 2006 .

[9]  Ersen B. Colkesen,et al.  Validation of a model to investigate the effects of modifying cardiovascular disease (CVD) risk factors on the burden of CVD: the rotterdam ischemic heart disease and stroke computer simulation (RISC) model , 2012, BMC Medicine.

[10]  William Hollingworth,et al.  Model Transparency and Validation , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[11]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .

[12]  S. Goldie,et al.  Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States , 2009, Annals of Internal Medicine.

[13]  Milton C. Weinstein,et al.  Incorporating Calibrated Model Parameters into Sensitivity Analyses , 2012, PharmacoEconomics.

[14]  G Scott Gazelle,et al.  Calibration of disease simulation model using an engineering approach. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  M. Weinstein,et al.  Life Expectancy Biases in Clinical Decision Modeling , 1995, Medical decision making : an international journal of the Society for Medical Decision Making.

[16]  S. Love,et al.  Survival Analysis Part II: Multivariate data analysis – an introduction to concepts and methods , 2003, British Journal of Cancer.

[17]  B. Gage,et al.  Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation , 2009, Annals of Internal Medicine.

[18]  Neff Walker,et al.  Mathematical models in the evaluation of health programmes , 2011, The Lancet.

[19]  Cathal Walsh,et al.  Bayesian Calibration of a Natural History Model with Application to a Population Model for Colorectal Cancer , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.

[20]  David G. Kleinbaum,et al.  Survival Analysis: A Self-Learning Text , 1997 .

[21]  Simon G Thompson,et al.  Uncertainty and validation of health economic decision models. , 2009, Health economics.

[22]  Natasha K. Stout,et al.  Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines , 2012, PharmacoEconomics.

[23]  M. D. John B. Wong Washington Pharmacogenomics of hepatitis C and decision analysis: A glimpse into the future , 2003 .

[24]  Milton C. Weinstein,et al.  Recent Developments in Decision-Analytic Modelling for Economic Evaluation , 2012, PharmacoEconomics.

[25]  P Barton,et al.  The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. , 2004, Health technology assessment.

[26]  J R Beck,et al.  A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. , 1982, The American journal of medicine.

[27]  J B Wong,et al.  Analytic Choices in Economic Models of Treatments for Rheumatoid Arthritis: What Makes a Difference? , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.

[28]  John B Wong,et al.  Pharmacogenomics of hepatitis C and decision analysis: A glimpse into the future , 2002, Hepatology.

[29]  A. O'Hagan,et al.  Bayesian calibration of computer models , 2001 .

[30]  C. Schmitt,et al.  Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. , 1999 .

[31]  Amy B. Knudsen,et al.  Evaluating Test Strategies for Colorectal Cancer Screening: A Decision Analysis for the U.S. Preventive Services Task Force , 2008, Annals of Internal Medicine.

[32]  Vivek Pawar,et al.  Methods of Model Calibration , 2012, PharmacoEconomics.

[33]  Karen M Kuntz,et al.  Multiparameter calibration of a natural history model of cervical cancer. , 2007, American journal of epidemiology.

[34]  Milton C Weinstein,et al.  Calibrating longitudinal models to cross-sectional data: the effect of temporal changes in health practices. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[35]  Erry,et al.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. , 1995, The New England journal of medicine.

[36]  Richard G. White,et al.  Calibrating Models in Economic Evaluation , 2012, PharmacoEconomics.

[37]  Murray Krahn,et al.  Conceptualizing a Model , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[38]  Theo Stijnen,et al.  Apparent and Internal Validity of a Monte Carlo–Markov Model for Cardiovascular Disease in a Cohort Follow-up Study , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.